Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Arnon Nagler, Myriam Labopin, Jonathan Canaani, Riitta Niittyvuopio, Gerard Socié, Nicolaus Kröger, Maija Itäla-Remes, Ibrahim Yakoub-Agha, Hélène Labussière-Wallet, Maria P Gallego-Hernanz, Eric Deconinck, Patrice Chevallier, Jürgen Finke, Jordi Esteve, Mohamad Mohty
While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. The analysis comprised MRD+ patients in first complete remission undergoing allo-SCT from a matched sibling donor or unrelated donor...
June 12, 2020: American Journal of Hematology
#22
Per Ljungman, Malgorzata Mikulska, Rafael de la Camara, Grzegorz W Basak, Christian Chabannon, Selim Corbacioglu, Rafael Duarte, Harry Dolstra, Arjan C Lankester, Mohamad Mohty, Silvia Montoto, John Murray, Régis Peffault de Latour, John A Snowden, Ibrahim Yakoub-Agha, Bregje Verhoeven, Nicolaus Kröger, Jan Styczynski
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
June 8, 2020: Bone Marrow Transplantation
#23
JOURNAL ARTICLE
Franziska Modemann, Francis Ayuk, Christine Wolschke, Maximilian Christopeit, Dietlinde Janson, Ute-Marie von Pein, Nicolaus Kröger
Acute graft-versus-host disease (aGVHD) is a serious complication after stem cell transplantation and is associated with high non-relapse mortality. If steroid treatment as first-line therapeutic approach fails, treatment options are limited. In retrospective studies, ruxolitinib, a selective Janus kinase 1/2 inhibitor as well as extracorporeal photopheresis (ECP) could show high efficacy in treatment of steroid refractory acute and chronic GVHD. Here, we report single-center experience of combining JAK-inhibitor treatment with ECP in 18 patients with severe steroid refractory aGVHD of lower GI-tract...
May 23, 2020: Bone Marrow Transplantation
#24
REVIEW
Per Ljungman, Malgorzata Mikulska, Rafael de la Camara, Grzegorz W Basak, Christian Chabannon, Selim Corbacioglu, Rafael Duarte, Harry Dolstra, Arjan C Lankester, Mohamad Mohty, Silvia Montoto, John Murray, Régis Peffault de Latour, John A Snowden, Ibrahim Yakoub-Agha, Bregje Verhouven, Nicolaus Kröger, Jan Styczynski
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients...
May 13, 2020: Bone Marrow Transplantation
#25
JOURNAL ARTICLE
Francesca Lorentino, Myriam Labopin, Fabio Ciceri, Luca Vago, Katharina Fleischhauer, Boris Afanasyev, Nicolaus Kröger, Jan J Cornelissen, Montserrat Lovira, Ellen Meijer, Antonin Vitek, Ahmet Elmaagacli, Didier Blaise, Annalisa Ruggeri, Christian Chabannon, Arnon Nagler, Mohamad Mohty
HLA-matching largely contributes to unrelated donor hematopoietic cell transplantation (UD-HCT) success but, due to the selective deletion of alloreactive T-cells, post-transplantation cyclophosphamide (PTCy) could modulate its negative impact on outcomes. We retrospectively compared acute leukemia patients receiving 10/10 or 9/10 HLA allele-matched UD-HCT with PTCy-GvHD prophylaxis between 2010 and 2017, reported to EBMT registry. The 100-day incidence of grade ≥2 and grade ≥3 aGvHD were comparable for 10/10 and 9/10 UD (28% versus 28%, p = 0...
February 2021: Leukemia
#26
REVIEW
Per Ljungman, Malgorzata Mikulska, Rafael de la Camara, Grzegorz W Basak, Christian Chabannon, Selim Corbacioglu, Rafael Duarte, Harry Dolstra, Arjan C Lankester, Mohamad Mohty, Silvia Montoto, John Murray, Régis Peffault de Latour, John A Snowden, Ibrahim Yakoub-Agha, Bregje Verhoeven, Nicolaus Kröger, Jan Styczynski
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients...
November 2020: Bone Marrow Transplantation
#27
JOURNAL ARTICLE
Krisstina Gowin, Karen Ballen, Kwang Woo Ahn, Zhen-Huan Hu, Haris Ali, Murat O Arcasoy, Rebecca Devlin, Maria Coakley, Aaron T Gerds, Michael Green, Vikas Gupta, Gabriela Hobbs, Tania Jain, Malathi Kandarpa, Rami Komrokji, Andrew T Kuykendall, Kierstin Luber, Lucia Masarova, Laura C Michaelis, Sarah Patches, Ashley C Pariser, Raajit Rampal, Brady Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Vaibhav Agrawal, Mahmoud Aljurf, Miguel Angel Diaz, Belinda R Avalos, Ulrike Bacher, Asad Bashey, Amer M Beitinjaneh, Jan Cerny, Saurabh Chhabra, Edward Copelan, Corey S Cutler, Zachariah DeFilipp, Shahinaz M Gadalla, Siddhartha Ganguly, Michael R Grunwald, Shahrukh K Hashmi, Mohamed A Kharfan-Dabaja, Tamila Kindwall-Keller, Nicolaus Kröger, Hillard M Lazarus, Jane L Liesveld, Mark R Litzow, David I Marks, Sunita Nathan, Taiga Nishihori, Richard F Olsson, Attaphol Pawarode, Jacob M Rowe, Bipin N Savani, Mary Lynn Savoie, Sachiko Seo, Melhem Solh, Roni Tamari, Leo F Verdonck, Jean A Yared, Edwin Alyea, Uday Popat, Ronald Sobecks, Bart L Scott, Ryotaro Nakamura, Ruben Mesa, Wael Saber
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0...
May 12, 2020: Blood Advances
#28
JOURNAL ARTICLE
Johanna M Eberhard, Mathieu Angin, Caroline Passaes, Maria Salgado, Valerie Monceaux, Elena Knops, Guido Kobbe, Björn Jensen, Maximilian Christopeit, Nicolaus Kröger, Linos Vandekerckhove, Jon Badiola, Alessandra Bandera, Kavita Raj, Jan van Lunzen, Gero Hütter, Jürgen H E Kuball, Carolina Martinez-Laperche, Pascual Balsalobre, Mi Kwon, José L Díez-Martín, Monique Nijhuis, Annemarie Wensing, Javier Martinez-Picado, Julian Schulze Zur Wiesch, Asier Sáez-Cirión
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only medical intervention that has led to an HIV cure. Whereas the HIV reservoir sharply decreases after allo-HSCT, the dynamics of the T cell reconstitution has not been comprehensively described. We analyzed the activation and differentiation of CD4+ and CD8+ T cells, and the breadth and quality of HIV- and CMV-specific CD8+ T cell responses in 16 patients with HIV who underwent allo-HSCT (including five individuals who received cells from CCR5Δ32/Δ32 donors) to treat their underlying hematological malignancy and who remained on antiretroviral therapy (ART)...
May 6, 2020: Science Translational Medicine
#29
JOURNAL ARTICLE
Sandra Thiele, Simone Goebel, Nicolaus Kröger, Anya Pedersen
OBJECTIVE: Prior to hematopoietic stem cell transplantation (HSCT), and despite the high objective risks associated with HSCT, fear of progression (FoP) has only sparsely been studied in patients with acute leukemia until now. The aim of this study was the assessment of the prevalence of FoP, and any relevant correlates and typical concerns. METHODS: We included 59 adult patients with acute leukemia who were tested prior to their first HSCT during an in-patient stay...
August 2020: Psycho-oncology
#30
JOURNAL ARTICLE
Juan Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, Dietrich Beelen, Marie Robin, Martin Bornhäuser, Emanuele Angelucci, Antonin Vitek, Igor Wolfgang Blau, Riitta Niittyvuopio, Jürgen Finke, Jan J Cornelissen, Jakob Passweg, Peter Dreger, Eefke Petersen, Lothar Kanz, Jaime Sanz, Tsila Zuckerman, Nienke Zinger, Simona Iacobelli, Patrick Hayden, Tomasz Czerw, Donal McLornan, Ibrahim Yakoub-Agha
We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the European Society for Blood and Marrow Transplantation included 2916 myelofibrosis patients who underwent first allo-HCT from an HLA-identical sibling or unrelated donor between 2000 and 2016. After a median follow-up of 4.7 years from transplant, projected median survival of the series was 5...
January 2021: Leukemia
#31
JOURNAL ARTICLE
Boris Fehse, Nicolaus Kröger, Carol Stocking, Axel Zander
No abstract text is available yet for this article.
April 10, 2020: Experimental Hematology
#32
MULTICENTER STUDY
Stefano Giardino, Regis P de Latour, Mahmoud Aljurf, Dirk-Jan Eikema, Paul Bosman, Yves Bertrand, Abdelghani Tbakhi, Wolfgang Holter, Martin Bornhäuser, Claudia Rössig, Birgit Burkhardt, Marco Zecca, Boris Afanasyev, Gerard Michel, Arnold Ganser, Amal Alseraihy, Mouhab Ayas, Duygu Uckan-Cetinkaya, Benedicte Bruno, Katharine Patrick, Peter Bader, Maija Itälä-Remes, Vanderson Rocha, Charlotte Jubert, Miguel A Diaz, Peter J Shaw, Luiz G D Junior, Franco Locatelli, Nicolaus Kröger, Maura Faraci, Filomena Pierri, Edoardo Lanino, Maurizio Miano, Antonio Risitano, Marie Robin, Carlo Dufour
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative for bone marrow failure in patients with Fanconi anemia (FA), but the presence of a malignant transformation is associated with a poor prognosis and the management of these patients is still challenging. We analyzed outcome of 74 FA patients with a diagnosis of myelodysplastic syndrome (n = 35), acute leukemia (n = 35) or with cytogenetic abnormalities (n = 4), who underwent allo-HSCT from 1999 to 2016 in EBMT network. Type of diagnosis, pre-HSCT cytoreductive therapies and related toxicities, disease status pre-HSCT, donor type, and conditioning regimen were considered as main variables potentially influencing outcome...
July 2020: American Journal of Hematology
#33
JOURNAL ARTICLE
Francis Ayuk, Boris Fehse, Dietlinde Janson, Carolina Berger, Kristoffer Riecken, Nicolaus Kröger
No abstract text is available yet for this article.
April 2, 2020: Haematologica
#34
JOURNAL ARTICLE
Markus Samek, Katharina Iversen, Cristina Belmar Campos, Laura Berneking, Claudia Langebrake, Christine Wolschke, Francis Ayuk, Nicolaus Kröger, Maximilian Christopeit
OBJECTIVES: During allogeneic hematopoietic stem cell transplantation (allo-SCT), infections significantly contribute to morbidity and mortality. A monocentric prospective analysis was performed to assess epidemiology, risk factors, and outcomes of infections during the peri-transplant period. METHODS: Data were recorded prospectively using a predefined questionnaire. RESULTS: In 2015, 163 consecutive patients, 37.4% female, median age 59 (range 18-79) years received 166 allo-SCT...
August 2020: European Journal of Haematology
#35
JOURNAL ARTICLE
Nico Gagelmann, Nicolaus Kröger
No abstract text is available yet for this article.
March 26, 2020: JAMA Oncology
#36
JOURNAL ARTICLE
Levin Schriewer, Kerstin Schütze, Katharina Petry, Julia Hambach, William Fumey, Julia Koenigsdorf, Natalie Baum, Stephan Menzel, Björn Rissiek, Kristoffer Riecken, Boris Fehse, Jana Larissa Röckendorf, Joanna Schmid, Birte Albrecht, Hans Pinnschmidt, Francis Ayuk, Nicolaus Kröger, Mascha Binder, Gunter Schuch, Timon Hansen, Friedrich Haag, Gerhard Adam, Friedrich Koch-Nolte, Peter Bannas
Rationale : CD38 is a target for the therapy of multiple myeloma (MM) with monoclonal antibodies such as daratumumab and isatuximab. Since MM patients exhibit a high rate of relapse, the development of new biologics targeting alternative CD38 epitopes is desirable. The discovery of single-domain antibodies (nanobodies) has opened the way for a new generation of antitumor therapeutics. We report the generation of nanobody-based humanized IgG1 heavy chain antibodies (hcAbs) with a high specificity and affinity that recognize three different and non-overlapping epitopes of CD38 and compare their cytotoxicity against CD38-expressing hematological cancer cells in vitro , ex vivo and in vivo ...
2020: Theranostics
#37
MULTICENTER STUDY
Donal P McLornan, Vittoria Malpassuti, Anne Lippinkhof-Kozijn, Victoria Potter, Dietrich Beelen, Donald Bunjes, Henrik Sengeloev, Aleksandar Radujkovic, Jakob Passweg, Yves Chalandon, Nicolaus Kröger, Gerald G Wulf, Jan-Erik Johansson, Fabio Ciceri, Martin Bornhäuser, Ernst Holler, Blandine Guffroy, Sonja Martin, Andreas Neubauer, Martin Gramatski, Marie Robin, Simona Iacobelli, Patrick Hayden, Juan C Hernández Boluda, Tomasz Czerw, Ibrahim Yakoub-Agha
Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined...
August 2020: British Journal of Haematology
#38
JOURNAL ARTICLE
Jakob R Passweg, Helen Baldomero, Christian Chabannon, Grzegorz W Basak, Selim Corbacioglu, Rafael Duarte, Harry Dolstra, Arjan C Lankester, Mohamad Mohty, Silvia Montoto, Régis Peffault de Latour, John A Snowden, Jan Styczynski, Ibrahim Yakoub-Agha, Nicolaus Kröger
Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic)...
February 17, 2020: Bone Marrow Transplantation
#39
JOURNAL ARTICLE
Boris Fehse, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Nicolaus Kröger, Francis A Ayuk
Treatment with axicabtagene ciloleucel (Axi-cel) CD19-CAR-T (chimeric antigen receptor T) cells has been approved for refractory/relapsed diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL). Because treatment success as well as side effects might depend on CAR-T cell expansion in vivo , we aimed at developing digital PCR (dPCR) assays for detection and quantification of CAR-T cells. To this end, we cloned and sequenced the complete cDNA of the CAR construct. We designed different combinations of primers and dual-labeled hydrolysis probes located in various CAR regions...
March 13, 2020: Molecular Therapy. Methods & Clinical Development
#40
JOURNAL ARTICLE
Mina D Aziz, Jay Shah, Urvi Kapoor, Christina Dimopoulos, Sarah Anand, Allan Augustine, Francis Ayuk, Mohammed Chaudhry, Yi-Bin Chen, Hannah K Choe, Aaron Etra, Stephanie Gergoudis, Matthew J Hartwell, Elizabeth O Hexner, William J Hogan, Carrie L Kitko, Steven Kowalyk, Nicolaus Kröger, Pietro Merli, George Morales, Ryotaro Nakamura, Rainer Ordemann, Michael A Pulsipher, Muna Qayed, Ran Reshef, Wolf Rösler, Tal Schechter, Elisabeth Schreiner, Hrishikesh Srinagesh, Matthias Wölfl, Kitsada Wudhikarn, Gregory Yanik, Rachel Young, Umut Özbek, James L M Ferrara, John E Levine
The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-versus-host disease (GVHD) leads to prolonged intensive immunosuppression and possible blunting of the GVL effect. Strategies to reduce immunosuppression in order to prevent relapse have been offset by increases in severe GVHD and nonrelapse mortality (NRM). We recently validated the MAGIC algorithm probability (MAP) that predicts the risk for severe GVHD and NRM in asymptomatic patients using serum biomarkers...
July 2020: Leukemia
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
